Plain-English translation of NCT05940961 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help treat acute lymphoblastic leukemia (ALL) that comes back after a stem cell transplant. The goal is to see if this medication can stop the cancer from growing again and help patients live longer. Researchers believe this treatment may work well because it has shown promise in helping other patients with similar blood cancers.
Even after a stem cell transplant, leukemia sometimes comes back, and patients whose cancer returns are at high risk for worse outcomes. This trial exists to see whether this medication can prevent the cancer from returning or stop it early, giving patients a better chance at long-term survival.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive intravenous infusions (IV medicine through your vein) given over several days in a treatment cycle. In the first cycle, you'll receive three doses spread over 15 days, and the dose may adjust based on how your body responds. Depending on whether the medication successfully stops the cancer cells, your second cycle may involve a different dosing schedule. You'll have regular blood tests and check-ins to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China